nanoenzalutamide / Nanoform - LARVOL DELTA

Nanoform’s biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned (PRNewswire) - "EU/US pivotal studies are planned to start in 4Q24, with the read-out in 1Q25...'We expect nanoenzalutamide to be the first nanoformed medicine to reach the market - with a planned launch in 2027/28 in the US/EU - and to be a revenue driver for Nanoform already in the upcoming years.'"

Clinical data • Launch Europe • Launch US • New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide (PRNewswire) - "Nanoform Finland Plc...announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD); formulation of nanoenzalutamide and Xtandi^®, the number one prescribed androgen receptor inhibitor first approved by the FDA in 2012 to treat prostate cancer....Clinical trial read-out is expected during Q1 2024."

Clinical data • Trial status • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor